Related Experiment Video
Updated: Jun 12, 2026
Promoting 3-D Aggregation of FACS Purified Thymic Epithelial Cells with EAK 16-II/EAKIIH6 Self-assembling Hydrogel
Published on: June 27, 2016
[Design and activity analysis of chimeric epidermal growth factor fusion vaccine E5T-mSEA]
Qingqing Yin1, Haiwei Jia, Yanhong Zhang
1Department of Life Science, Anhui University, Hefei 230039, China.
Abstract:
Epidermal growth factor receptor (EGFR) and its ligands (EGF and TGFalpha) are over-expressed in a variety of tumors. Immunization EGF-carrier protein inhibits tumor growth through abrogating binding of EGF to EGFR. Here, a chimeric protein of EGF and TGFalpha (E5T) was genetically fused to Staphylococcal enterotoxin A (SEA), a bacterial superantigenic protein which promotes humoral B cell response through enhancement of Ag-specific CD4 T cells activity. The resulted fusion proteins were expressed in Escherichia coli and purified though metal chelating affinity chromatography. Immunization of E5T-mSEA fusion protein in mice induced production of high titers antibodies, which recognize both EGF and TGFalpha. Anti- E5T-mSEA serum at dilution of 1:10 significantly inhibited growth of A431 cell lines but had little effect on 293T cell lines.
Insights
This study developed a novel fusion protein to target tumors overexpressing epidermal growth factor receptor (EGFR). Immunization with this fusion protein generated antibodies that inhibited tumor cell growth.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Epidermal growth factor receptor (EGFR) and its ligands (EGF, TGFalpha) are overexpressed in various tumors.
- Targeting EGFR signaling is a key strategy in cancer therapy.
- Previous studies showed EGF-carrier protein immunization inhibits tumor growth by blocking EGF-EGFR binding.
Purpose of the Study:
- To create a novel fusion protein combining EGF and TGFalpha (E5T) with Staphylococcal enterotoxin A (SEA).
- To evaluate the immunogenicity and anti-tumor efficacy of the E5T-mSEA fusion protein.
Main Methods:
- Genetic fusion of E5T and mSEA.
- Expression and purification of the fusion protein in Escherichia coli using metal chelating affinity chromatography.
- Immunization of mice with the fusion protein.
- Assessment of antibody production and tumor cell growth inhibition.
Main Results:
- The E5T-mSEA fusion protein was successfully expressed and purified.
- Immunization induced high-titer antibodies recognizing both EGF and TGFalpha.
- The resulting anti-serum significantly inhibited the growth of A431 tumor cells (EGFR-overexpressing).
- Minimal effect on 293T cells (non-tumorigenic) was observed.
Conclusions:
- The E5T-mSEA fusion protein is immunogenic and elicits antibodies that inhibit tumor cell growth.
- This approach offers a potential new strategy for targeting EGFR-overexpressing tumors.